Neutrophilic granulocytes in the peripheral circulation appear to be a morphologically homogenous, short-lived, fully differentiated group of cells. These cells have a significant role in nonspecific antibody-and complement-directed host defense. Various correlates of neutrophil function have been identified and used to monitor the activity of these cells and their abnormalities (1-4).. Although in vitro induction ofneutrophil activity appears to mimic in vivo stimulation, different stimuli often induce the same response, suggesting that a common pathway may be activated through different cell surface receptors. Alternatively, or in addition, different functional activities might be associated with different subpopulations of neutrophils. In fact, there is some evidence of functionally distinct neutrophil subpopulations (5, 6) .
A number of monoclonal antibodies reactive to antigens associated with human myeloid cells have recently been reported, which may be useful in dissecting neutrophil biological activities. Several of these antibodies react with antigens associated with both neutrophils and monocytes (7) (8) (9) . Certain other monoclonal antibodies are specific for and react with the entire circulating neutrophil population (NCD 1, 1/12/13) (4, 10). One ofthese antibodies, NCD 1, as well as one whose specificity has not been defined (NCD 3), reacts with neutrophils and inhibits some but not all neutrophil functional correlates (4, 11) . NCD 1 blocks lysozomal enzyme release and chemotaxis, whereas NCD 3 only inhibits N-formylmethionylleucylphenylalanine-induced chemotaxis. The unique specificities of these monoclonal antibodies suggest that there may be a large number of antigens that are characteristic of myeloid cells.
In the present report we describe the reactivities of three different myeloid-specific monoclonal antibodies-PMN 6, PMN 29, and AML-2-23-which appear to be useful in studies of neutrophils, neutrophil subpopulations, and myeloid leukemias.
MATERIALS AND METHODS Production of Hybridomas. Hybrid cells making monoclonal antibodies to human neutrophils were prepared as described, with neutrophils from normal donors or blast cells from a patient with acute myelomonocytic leukemia used as immunogens (12, 13) . Clones PMN 6, PMN 29, and AML-2-23, derived from two different fusions, were selected for study on the basis of their specific reactivity to neutrophils. Immunoglobulin class and subclass of each monoclonal antibody were determined as described (12) .
Cells. Neutrophils used for immunizations and screenings were isolated from the peripheral blood of normal donors. Mononuclear cells were separated from neutrophils and erythrocytes (RBC) by Ficoll/Hypaque gradient centrifugation (14) . RBC were separated from neutrophils by sedimentation in 2% dextran and lysis by osmotic shock. Monocytes used for screening were prepared from the mononuclear fraction by adherence to plastic Petri dishes pretreated with autologous serum for 15 min at 37°C. Both the monocyte and normal lymphocyte (nonadherent mononuclear cell) preparations were stained for anaphthyl butyrate esterase (nonspecific esterase) in order to assess their purity (15) . In addition, all cell populations were stained with Wright/Giemsafor morphologic analysis. Platelets were prepared by centrifuging anticoagulated (0.4% sodium citrate) whole blood for 10 min at 250 x g. The supernatant was collected and the platelets were pelleted by centrifugation at 400 x g for 6 min. RBC were prepared by centrifuging anticoagulated whole blood and removing the supernatant and buffy coat.
The (21, 22) . Cells from patients with acute myelocytic leukemia, acute lymphocytic leukemia, or chronic lymphocytic leukemia were separated from blood by Ficoll/Hypaque gradient centrifugation and cryopreserved at -70°C prior to use. After thawing, the cells were assessed for viability by phase-contrast microscopy and acridine orange/ethidium bromide staining; they were used only if >95% were viable. Two acute myelocytic leukemia samples, AML-B and AML-C, were determined by morphological and histochemical staining criteria to be myelomonocytic leukemias (M4 in the French, American, and British classifications) (23) . AML-A was a monocytic leukemia (M5) and AML-D was an undifferentiated myeloid leukemia (Ml).
Binding and Cytotoxicity Assays. Binding of monoclonal antibodies to cells was measured by replicate radioimmunoassay (RIA) as described (12, 24) . The ability of these monoclonal antibodies to mediate complement-dependent cytotoxicity of leukemia and normal cells was measured in a modified microcytotoxicity assay (12, 25) .
Cytofluorographic Analysis. Cells were incubated at 107/ ml in 300 ,ul of hybridoma culture supernatant for 30 min at 4°C. Supernatants from the parent myeloma line P3-X63Ag8 and from a hybridoma secreting an IgM antibody reactive with an irrelevant antigen were used as controls. The cells were washed twice in phosphate-buffered saline containing 0.1% bovine serum albumin and 0.05% sodium azide and incubated with 25 ,ul of a 1: 10 dilution of affinity-purified fluorescein-conjugated F(ab')2 goat anti-mouse immunoglobulin for 30 min at 4°C. They were then washed and resuspended in 0.3 ml of the buffered saline/albumin/azide. The Ortho (Westwood, MA) Cytofluorograph system 50H with multichannel distribution analyzer 2103 and Ortho 2150 computer systems was used to quantitate binding of the monoclonal antibodies to various cell populations. (Fig. LA) indicated that the majority of cells showed very intense staining. AML-2-23 showed a different fluorescence profile on neutrophils (Fig. 1B) (Table 2) . Neutrophils stained with PMN 29 showed a wide range of fluorescence intensities ( Fig. 2A) . The majority of neutrophils stained with PMN 6 occurred in the lower fluorescence range and yet the total range offluorescence intensities observed with PMN 6 was also very broad.
RESULTS
Mean intensity of fluorescence staining was examined for comparison ofaverage quantity ofantigen on cells (Table 3 ). The antigen detected by AML-2-23 was expressed in far greater amounts on monocytes than on neutrophils from the same individual. Neutrophils from different donors also expressed varying mean amounts of this antigen. This variation was also observed with staining by antibody PMN (Tables 5 and 6 ). PMN 6 was consistently cytotoxic to 30-75% of neutrophils from different individuals whereas PMN 29 was cytotoxic to virtually 100% of neutrophils from all individuals tested. AML-2-23 mediated cytotoxicity against normal monocytes, leukemia samples with myelomonocytic or monocytic morphology (12) , and the HL-60 cell line to a titer of 2.5 x iO-'. However, despite binding to neutrophils, AML-2-23 did not mediate cytotoxicity of these cells. PMN 6 and PMN 29 were also cytotoxic to myelomonocytic leukemia samples. None of these antibodies reacted with lymphocytic leukemia cells.
DISCUSSION
In this report we describe the properties of three monoclonal antibodies specific to myeloid cells. Two are specific for neutrophils, PMN 6 and PMN 29; the third, AML-2-23, is specific 5376 Immunology: Ball et aL for an antigen present on both neutrophils and monocytes. All are unreactive with lymphocytes, RBC, and platelets. More detailed analysis by cytofluorography indicates that PMN 29 binds to virtually all neutrophils but PMN 6 and AML-2-23 react with a subpopulation of these cells. AML-2-23 also binds to 68-85% of normal human monocytes. None ofthese antibodies reacts with previously described neutrophil alloantigens (26) because all individuals studied expressed each antigen.
Two other human neutrophil-specific monoclonal antibodies have been reported to date. One identifies an antigen (My-i) present on neutrophils, bone marrow neutrophil precursors, and blast cells ofsome patients with myeloid leukemia (10) . The other monoclonal antibody (NCD 1) was found to inhibit neutrophil chemotaxis and degranulation (4) . NCD 3, a monoclonal antibody of undefined specificity, has been reported to inhibit N-formylmethionylleucylphenylalanine-induced chemotaxis of neutrophils (11) . Like PMN 29, all of these antibodies bind to >95% of neutrophils. Although certain differences in the binding patterns ofthese antibodies exist, insufficient data are available to permit definitive comparison of their reactivities.
Monoclonal antibody AML-2-23 recognizes a determinant shared by both monocytes and neutrophils, as do a number of other monoclonal antibodies (4, 7-9, 27, 28). In addition, some hybridoma-derived antibodies that react only with monocytes 50-75 Cytotoxicity was estimated by dye exclusion in microtiter wells. Lymphocytes were not killed by any of these antibodies.
have been described (9, 29, 30 Immunology: Ballet al.
Proc. Natd Acad. Sci. USA 79 (1982) tion in the circulation or functional diversity or both. The amount of antigen PMN 29 varied widely among neutrophils yet was expressed on these cells in greater quantity than the antigens bound by AML-2-23 and PMN 6 . Based upon studies of myeloid cell lines, normal neutrophils, and monocytes, each of the three antigens appears to have a characteristic quantitative and qualitative distribution on myeloid cells at various stages of maturation. Some immature blasts ofthe KG-la, KG-1, and K562 cell lines only express the PMN 29 antigen whereas the more differentiated cells ofthe HL-60 line display all three antigens to some degree. In contrast to the HL-60 line, a larger percentage of mature normal neutrophils express the PMN 29 and AML-2-23 antigens; the number of PMN 6-positive cells is the same in both cases. Studies on differentiation ofthe HL-60 cell line with dimethyl sulfoxide and phorbol esters (31) may provide more insight into the relative expression of these antigens on myeloid precursors at distinct stages of morphologic development.
The selective reactivity and cytotoxicity ofthese monoclonal antibodies to many myeloid leukemia cell samples may prove to be important in the identification and subgrouping ofmyeloid leukemia cells. Based on these and other studies (12, 24) , it would appear that blast cells from many patients with acute myelocytic leukemia bear at least two ofthese myeloid antigens whereas all lymphocytic leukemia samples studied have been negative. PMN 6 and PMN 29 were found to mediate complement-dependent cytotoxicity in two cases of acute myelocytic leukemia studied whereas AML-2-23 selectively mediated lysis in six of six acute myelomonocytic and acute monocytic leukemia cell samples (12) but not in an undifferentiated myelogenous leukemia (AML-D). Thus, all three ofthese antibodies show considerable promise for both the diagnosis and treatment of leukemia. Furthermore, these monoclonal antibodies have considerable potential for investigations of neutrophils in disease states. Patients with congenital diseases in which disorders ofnormal neutrophil function are manifest (chronic granulomatous disease and Chediak-Higashi syndrome) or diseases in which there is a marked propensity for infection (diabetes mellitus or sickle cell anemia), for example, may have altered proportions of neutrophil subpopulations that reflect their functional capacities.
